Abstract: A diagnostic contrast composition includes a carrier fluid and a non-decaying gas-evolving fluid incorporated in the carrier fluid. The gas-evolving fluid has a vapor pressure sufficient to evolve the gas from a circulatory system within a lung of a patient. The gas-evolving fluid is a composition containing a sufficient quantity of atoms with an atomic number higher than 8 to provide an increased absorption sufficient to increase a Hounsfield Unit measurement in an image in a CT imaging system. The gas-evolving fluid is selected from the group consisting of xenon gas, krypton gas, sulfur hexafluoride, a perfluorocarbon, a brominated perfluorocarbon, and combinations thereof. The carrier fluid is selected from the group consisting of water, saline, saline comprising one or more blood proteins, and saline comprising dissolved lipids.

Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

Abstract: A nanoparticle for diagnostic, therapeutic, and/or theranostic applications includes a rod-shaped plant virus like particle (VLP), one or more gadolinium T1 contrast agents conjugated to an interior surface of the VLP, and a layer of polydopamine (PDA) coated over a portion of the exterior surface of the VLP.

Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

Abstract: The present invention relates to a composition for material delivery, including exosome mimetics derived from red blood cells, and a use thereof and the composition for material delivery according to an exemplary embodiment of the present invention includes exosome mimetics derived from red blood cells, which are capable of being loaded with a drug, a radioactive material, or a fluorescent material, and thus may be usefully utilized for a drug delivery use, a cell labeling use, a contrast medium, or the like, and when the composition for material delivery according to an exemplary embodiment of the present invention is used, treatment and diagnosis may be simultaneously performed.

Abstract: Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

Abstract: Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.

Abstract: The present invention provides a compound represented by the formula (1) or a salt thereof, or a complex of the compound or the salt with a metal, in the formula (1), A1 represents a chelate group; R1 represents a hydrogen atom or the like; R2 represents a hydrogen atom or the like; and Z1, Z2, Z3, Z4, and Z5 are the same or different and each represent a nitrogen atom or CR3 or the like wherein R3 represents a hydrogen atom or an optionally substituted C1-6 alkyl group or the like; L1 represents a group represented by the formula (3) wherein R13, R14, R15, and R16 are the same or different and each represent a hydrogen atom or the like; L2 represents an optionally substituted C1-6 alkylene group; and L3 represents an optionally substituted C1-6 alkylene group.

Abstract: The present invention includes a construct that comprises at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention also includes a pharmaceutical composition comprising a construct comprising at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention further includes a method of imaging a tissue or organ in a subject, a method of delivering a therapeutic cargo to a tissue or organ in a subject, and a method of treating a disease or disorder in a subject.

Abstract: There is described a method for preparation of an imaging medium via transfer from a hyperpolarised singlet state that is not parahydrogen, said method comprising the steps of: (i) preparing a system containing: parahydrogen; a magnetisation transfer complex, with a molecular symmetry that allows the creation of a singlet state between spin pairs within it, said complex including a reversibly bound small molecule transference substrate; applying a magnetic field such that hyperpolarisation is transferred into the transfer complex, including the reversibly bound small molecule transference substrate; (ii) introducing a recipient complex capable of binding the small molecule transference substrate, said recipient complex including a recipient substrate, such that the recipient complex and recipient substrate, including the bound transference substrate, is hyperpolarised.

Abstract: A platinum sulfide protein nanoparticle having near-infrared photothermal effect and multi-modal imaging function, a preparation method therefor and an application thereof. The platinum sulfide nanoparticle having near-infrared photothermal effect and multi-modal imaging function is prepared in aqueous phase by means of formulation screening and process limitation. The nanoparticle has an ultra-small particle size and good stability as well as tumor targeting and photothermal effects and integrates functions of near-infrared imaging, CT imaging, and thermal imaging, so as to achieve high sensitivity, high resolution, and precise positioning of tumors, and to produce high-efficiency photothermal effects under the excitation of near-infrared light to kill tumor cells by thermal ablation, thereby achieving the purpose of efficient, safe, visual, and accurate treatment of tumors. The nanoparticle has the potential for further development and clinical application.

Abstract: The present invention relates to a diagnostic device and methods of using the same for diagnostic assays for monitoring the presence of biological samples wherein the device allows for the determination of at least two assay components on one sensor. More specifically, the invention relates to a multi-marker electrochemical impedance spectroscopy sensor comprising a plurality of molecular recognition elements wherein the sensor comprises multiple different molecular recognition element types that are tuned in a manner that alters the frequency of the molecular recognition element type such that it is at a detectably different frequency to the frequency of other molecular recognition element types on the same sensor.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: The present technology provides 13C- and 15N-labeled probes for imaging one or more mammalian cells using magnetic resonance. Thus, 13C- and 15N-labeled arginine (compound of formula I), xanthine (compounds of formula II and formula III), urea (compounds of formula IV), and glutamine (compounds of formula V), stereoisomers, tautomers, and pharmaceutically acceptable salts thereof are provided. Further methods of making the labelled probes and methods of using the probes to detect arginase, xanthine oxidase, and glutaminase metabolites and activity are provided.

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.

Abstract: The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.

Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.

Abstract: The pH-responsive ultrasensitive fluorescent nanoprobe is composed of pH-responsive matrix materials and fluorescent organic small molecule dyes. The pH-responsive matrix materials are calcium phosphate, calcium hydroxyphosphate, fluorapatite, calcium carbonate or ZIF series; the fluorescent organic small molecule dyes are positively charged dyes or negatively charged dyes. The preparation method includes: coating a positively charged dye with a negatively charged matrix material; coating a negatively charged dye with a negatively charged matrix material; and coating a negatively charged dye with a positively charged matrix material.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.